Roche: positive data in lupus nephritis

(CercleFinance.com) - Roche reports that the Phase III REGENCY study of Gazyva/Gazyvaro in active lupus nephritis met its primary endpoint, demonstrating statistically and clinically significant therapeutic benefits.


The Swiss healthcare company explains that its Gazyva/Gazyvaro is designed to target an underlying cause of lupus nephritis, with the aim of preventing or delaying progression to end-stage renal disease.

In the study, a higher proportion of people treated with Gazyva/Gazyvaro plus standard therapy achieved a complete renal response at 76 weeks compared to those treated with standard therapy alone.

This data will be shared with health authorities, including the US FDA and the European Medicines Agency, with the aim of making this potential new treatment option for lupus nephritis available as soon as possible.


Copyright (c) 2024 CercleFinance.com. All rights reserved.